Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, adding:
“Romiplostim, a thrombopoietin receptor agonist, has been shown to improve platelet counts and reduce chemotherapy dose modifications in patients with GI tumors receiving oxaliplatin-based regimens. However, whether this strategy translates into improvements in overall survival remains uncertain, or even unlikely, based on the supplemental figure 4.”
Quoting NEJM‘s post:
“RECITE: In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16). Full trial results.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Camargo, Gerald Soff
Read the Full Article.
Other articles featuring Antonio Calles on OncoDaily.
